RxDoctor Payments Data

Carlton Vollberg

Internal Medicine · Chattanooga, TNNPI 1730178450

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $28,100 of the $30,394 with a category attached, or 92.5%. Amgen accounts for 97.1% of it on its own, with 14 other manufacturers making up the rest. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$30,394in general payments, 2019–2025

Across 104 payments — averaging $292.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$30K
  • Amarin Pharma, Inc.$194
  • Novartis$174
  • AbbVie$98
  • Lilly USA, LLC$62
  • Antares Pharma, Inc.$54
  • plus $289 from 9 others
$74,217in research payments, 2019–2025

Across 11 payments — averaging $6747.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cleerly, Inc.$61K
  • AstraZeneca$13K

What the payments were for

  • Speaking & faculty fees$28,10092%
  • Travel & lodging$8753%
  • Food & beverage$1,4195%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,394 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab102$98,836
MounjaroTirzepatide73$82,464
JardianceEmpagliflozin67$55,215
OzempicSemaglutide30$50,025
TrulicityDulaglutide19$24,545
EliquisApixaban16$23,702
Tresiba Flextouch U-100Insulin Degludec14$10,961
Icosapent Ethyl18$5,731
SynthroidLevothyroxine Sodium19$2,163
Rosuvastatin Calcium148$2,102
Nebivolol Hcl13$1,617
Ezetimibe47$1,537
Nateglinide19$944
Losartan Potassium62$875
Gabapentin39$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$62$107,00992 claims
AbbVieSynthroid$98$2,16319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →